Clinical and Experimental Pediatrics

Review Article

Allergy

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Yong Ju Lee, Chang-Keun Kim

Clin Exp Pediatr. 2020;63(10):376-381. Published online February 5, 2020

Although the efficacy of montelukast is inferior to that of ICS, both physicians and parents prefer montelukast to ICSs.
EDN may be a useful biomarker for the treatment and monitoring of preschool children with asthma.
The US FDA requires boxed warning about serious neuropsychiatric events of montelukast, therefore, physicians should consider the benefits and risks of montelukast before prescribing it.

DOI: https://doi.org/10.3345/cep.2019.00325

Original Article

The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia

Sang Bum Kim, Jang Hoon Lee, Juyoung Lee, Seung Han Shin, Ho Sun Eun, Soon Min Lee, Jin A Sohn, Han Suk Kim, Byung Min Choi, Min Soo Park, Kook In Park, Ran Namgung, Moon Sung Park

Clin Exp Pediatr. 2015;58(9):347-353. Published online September 21, 2015

Crossref 10

Purpose

The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).

Methods

The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA)....

DOI: https://doi.org/10.3345/kjp.2015.58.9.347

Montelukast as an add-on therapy in bronchopulmonary dysplasia

He Min Kim, Ji Eun Song, Soon Min Lee, Min Soo Park, Kook In Park, Ran Namgung, Chul Lee

Clin Exp Pediatr. 2009;52(2):181-186. Published online February 15, 2009

Purpose : Inflammation plays a potential role in the pathogenesis of bronchopulmonary dysplasia (BPD). Strategies for preventing BPD include respiratory management, antioxidants, nutritional treatment, and others such as anti-inflammatory agents. We aimed to assess the safety, tolerability, and efficacy of montelukast (MK), a cysteinyl leukotriene 1 receptor antagonist, as an add-on therapy in BPD. Methods : In addition to currently available...

PDF

Cited By 21	Neurodevelopmental outcomes of preterm infants
Cited By 19	Long COVID in children and adolescents: prevalence, clinical manifestations, and management strategies
Cited By 17	Association of gut microbiota with obesity in children and adolescents
Cited By 16	Nonalcoholic fatty liver disease and insulin resistance in children
Cited By 16	Prevalence of anxiety, depression, and stress among parents of neonates admitted to neonatal intensive care unit: a systematic review and meta-analysis

Search